Skip to main content

Table 6 Univariable and multivariable survival analysis for OS using Cox proportional hazards models

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Group

Immune Biomarker

Univariable

Multivariable

HR (95% CI)

p-value

HR (95% CI)

p-value

Cohort A

ALCs

> = 800

< 800

10.15 (2.46, 41.76)

0.001

7.59 (1.33, 43.16)

0.022

CD4 plus CD8 counts

> = 500

< 500

2.90 (0.95, 8.84)

0.061

PD-L1 IHC

> = 50%

< 50%

2.54 (0.56, 11.45)

0.226

TMB

> = 10

< 10

0.42 (0.05, 3.51)

0.423

Cohort B

ALCs

> = 800

< 800

2.38 (0.89, 6.35)

0.084

CD4 plus CD8 counts

> = 500

< 500

3.03 (1.12, 8.20)

0.029

5.96 (1.60, 22.20)

0.008

PD-L1 IHC

> = 50%

< 50%

3.18 (0.97, 10.45)

0.056

TMB

> = 10

< 10

2.18 (0.71, 6.75)

0.175